Drug Profile
Ultra fast-acting insulin analogue - Adocia
Alternative Names: BC 106 Insulin Lispro; BC 222 Insulin Lispro; BC Lispro; BioChaperone Lispro; BioChaperone® insulin analogue; BioChaperone® insulin lispro; BioChaperone® Lispro U100; BioChaperone® Lispro U200; BioChaperone® Ultra Fast Lispro; THDB-0206Latest Information Update: 25 Sep 2023
Price :
$50
*
At a glance
- Originator Adocia
- Developer Adocia; Tonghua Dongbao Pharmaceutical
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant proteins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
- Phase II/III Type 1 diabetes mellitus
Most Recent Events
- 22 Sep 2023 Meitheal Pharmaceuticals enters into an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical to commercialize products in the US
- 06 May 2022 Phase-III trial for Type 2 diabetes mellitus in China (SC) (NCT05834868)
- 15 Oct 2021 Adocia and Tonghua Dongbao Pharmaceutical plans a phase III trial for Type-1 diabetes mellitus in the USA and Europe in 2022